I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 11% revenue growth to $114.4M, with exome/genome revenue up 17% and volumes up 32% year-over-year. Adjusted gross margin was 70%, and adjusted net income returned to positive territory. Full-year guidance was reiterated, and coverage expanded across Medicaid and commercial payers.Original document: GeneDx Holdings Corp. [WGS] SEC 8-K Current Report — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 11% revenue growth to $114.4M, with exome/genome revenue up 17% and volumes up 32% year-over-year. Adjusted gross margin was 70%, and adjusted net income returned to positive territory. Full-year guidance was reiterated, and coverage expanded across Medicaid and commercial payers.
Original document: GeneDx Holdings Corp. [WGS] SEC 8-K Current Report — Aug. 3 2026